TitleEPTRI (European Paediatric Translational Research Infrastructure)
Project id.158
Reference sectorBIOTECHNOLOGY
IP Protection LevelEPTRI is committed to open access, ensuring that qualitative and quantitative data generated is publicly and freely available for stakeholders to access and use. A specific attention will be given to the development of a dedicated IPR policy of the project, that will include coverage of IP policy, ownership, disclosure of inventions and licensing.
Description of the innovation projectA Research Infrastructure (RI) refers to facilities, resources, services to conduct top level research. The European Paediatric Translational RI (EPTRI) is a new RI in the context of the existing RIs intended to put together all the available competences and technologies useful to enhance research in paediatric medicines from drug discovery and early development phases to be translated into clinical phases and medicines use. CVBF has submitted the ID-EPTRI project as coordinator within the H2020-INFRADEV-01-2017 programme, approved in August 2017, to prepare the conceptual design report to realize EPTRI, describing the scientific and technical requirements and its key components.
State of dev.Model
Industrial applicationEPTRI will establish the right framework to speed-up the drug development process in paediatrics and to include the top-level research innovations in research for children’s health. It is expected that the existence of EPTRI will have a positive effect on the private sector including the paediatric specificities within the agenda of pharmaceutical companies and promoting the establishment of public-private partnerships developing new projects in the field of paediatrics as long-term outcome.
Market segmentThe main customers will be clinicians, researchers, SME, large Pharma, existing paediatric research communities, lay communities (charities, patients organisations). EPTRI business model will be value driven as it is based on value creation resulting from the enhancement of the competences and expertise that will be aggregated into the new RI.
Advantage factorEPTRI will have the innovative potential to become a distributed European RI able to better coordinate and foster cooperative efforts integrating existing expertise in the paediatric research. This will lead to a reduced fragmentation of the paediatric research landscape through harmonisation of procedures, implementation of common standards and the promotion of scientific excellence in research collaborations, so to maintain EPTRI to a high competitiveness at European level.
Commercial challengeThe new RI will represent a “paediatric common service” with three already established RIs (BBMRI, EATRIS, ECRIN) to harness efficiency and delivery of paediatric research activities and services strengthening collaboration within the scientific paediatric community. The competences that are expected to be developed will be transversally applicable to different therapeutic settings in paediatric field and can be potentially exploited by the R&D units of pharmaceutical companies.
Publications and Customer ReferecesRuggieri L, et all; on behalf of the GRiP Consortium. Successful private-public funding of paediatric medicines research. Eur J Pediatr. 2015; Giannuzzi V, et all. Clinical Trial Application in Europe. Sci Eng Ethics. 2015; Baiardi P et all. Innovative study design for paediatric clinical trials. Eur J Clin Ph. 2011 May;67 Suppl 1:109-15; Sturkenboom MC et all. Drug use in children: cohort study in three EU countries. BMJ. 2008 Nov 24;337:a2245.

Proposal of cooperation agreementCommercial representative, Know how transfer, Venture capital financing, Sub-contracting Agreement